In a nutshell The aim of this study was to determine the effect of biomarkers to tailor therapy in advanced prostate cancer in patients receiving abiraterone (Zytiga) treatment. The authors concluded that alkaline phosphatase (ALP- protein elevated in the blood), lactate dehydrogenase (LDH – protein involved in tumor growth) and prostate...
Read More
In a nutshell The authors aimed to determine the impact of prostate specific antigen (PSA) surge in hormone-resistant prostate cancer patients following abiraterone acetate (Zytiga) treatment. The authors concluded that PSA surge occurred in both chemotherapy-treated and chemotherapy-naïve patients treated with abiraterone acetate with no...
Read More
In a nutshell The authors determined the safety and effectiveness of abiraterone acetate (Zytiga) in patients with metastatic hormone-resistant prostate cancer. Some background Hormone therapy is a common treatment used in prostate cancer. It targets the male sex hormones active in prostate cancer, such as testosterone. Some patients...
Read More
